ANSWER: The prostate specific antigen (PSA) test is a way to screen for prostate cancer. It is not perfect, but when used properly, it can save lives by identifying men who have early prostate cancer ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

Stage 2 prostate cancer is considered localized, meaning the cancer is still confined entirely within the prostate gland and has not spread to nearby lymph nodes (node 0 or N0) or distant parts of the ...

“As a two-time prostate cancer survivor, I enjoy today as if it will be my last,” Jesse said. “I engage every man I meet ...

I am a 68-year old male in good health who exercises regularly, doesn’t take any medications, and doesn’t have a family history of prostate cancer. During my most recent yearly physical exam with my ...

Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

If a person has an "aggressive" prostate cancer with a Gleason score of 9, what does that mean? What's the outlook when it comes to survival rate and prognosis? Every cancer survivor is unique, of ...

Prostate cancer is an aggressive cancer that develops in the prostate gland, a small gland in the male reproductive system that produces fluid for semen. It is the most common cancer in men, after ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.